Table 2 Baseline characteristics of study participants
YY-312 group (n = 30) | Placebo group (n = 30) | P-value* | |
|---|---|---|---|
Sex | 0.573 | ||
Male | 10 (33.3%) | 8 (26.7%) | |
Female | 20 (66.7%) | 22 (73.3%) | |
Age (years) | 39.5 ± 11.2 | 41.7 ± 11.1 | 0.441 |
Height (cm) | 165.9 ± 9.8 | 162.9 ± 9.9 | 0.234 |
Weight (kg) | 75.0 ± 11.0 | 72.6 ± 10.8 | 0.400 |
BMI (kg/m2) | 27.1 ± 1.5 | 27.2 ± 1.2 | 0.692 |
WC (cm) | 88.3 ± 6.5 | 89.0 ± 7.1 | 0.705 |
Body fat (%) | 32.2 ± 5.5 | 32.9 ± 4.6 | 0.562 |
BFM (kg) | 22.6 ± 3.8 | 22.6 ± 3.6 | 0.961 |
LBM (kg) | 48.6 ± 10.0 | 46.5 ± 8.8 | 0.392 |
T-Chol (mg/dL) | 202.4 ± 40.2 | 206.8 ± 44.1 | 0.689 |
TG (mg/dL) | 111.0 ± 58.6 | 126.4 ± 107.5 | 0.493 |
HDL-C (mg/dL) | 53.1 ± 10.1 | 57.2 ± 10.5 | 0.128 |
LDL-C (mg/dL) | 128.4 ± 31.5 | 126.8 ± 34.1 | 0.848 |
FPG (mg/dL) | 91.5 ± 10.3 | 91.1 ± 7.7 | 0.843 |
AST (IU/L) | 21.4 ± 5.5 | 22.2 ± 5.4 | 0.572 |
ALT (IU/L) | 19.4 ± 6.9 | 22.1 ± 9.7 | 0.223 |
BUN (mg/dL) | 11.8 ± 2.7 | 13.6 ± 4.1 | 0.051 |
Creatinine (mg/dL) | 0.7 ± 0.2 | 0.7 ± 0.1 | 0.663 |
SBP (mmHg) | 122.7 ± 12.4 | 119.9 ± 16.5 | 0.455 |
DBP (mmHg) | 77.4 ± 9.5 | 75.5 ± 9.2 | 0.435 |
Energy intake (Kcal/day) | 1511.6 ± 485.9 | 1464.8 ± 289.5 | 0.654 |